Currently, there are 231.93M common shares owned by the public and among those 231.44M shares have been available to trade.
The company’s stock has a 5-day price change of 1.81% and -28.35% over the past three months. ELV shares are trading -20.91% year to date (YTD), with the 12-month market performance down to -20.07% lower. It has a 12-month low price of $362.21 and touched a high of $567.26 over the same period. ELV has an average intraday trading volume of 1.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.36%, -8.21%, and -25.01% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Elevance Health Inc (NYSE: ELV) shares accounts for 90.41% of the company’s 231.93M shares outstanding.
It has a market capitalization of $86.49B and a beta (3y monthly) value of 0.84. The stock’s trailing 12-month PE ratio is 13.59, while the earnings-per-share (ttm) stands at $27.43. The company has a PEG of 1.51 and the debt-to-equity ratio at 0.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.98% over the week and 2.50% over the month.
Earnings per share for the fiscal year are expected to increase by 0.12%, and 5.21% over the next financial year. EPS should shrink at an annualized rate of 9.01% over the next five years, compared to 12.18% over the past 5-year period.
BofA Securities coverage for the Elevance Health Inc (ELV) stock in a research note released on July 18, 2024 offered a Neutral rating with a price target of $530. Morgan Stanley was of a view on June 24, 2024 that the stock is Overweight, while Robert W. Baird gave the stock Outperform rating on May 30, 2024, issuing a price target of $649. Barclays on their part issued Overweight rating on March 06, 2024.
